Last updated on August 2018

MCLA-117 in Acute Myelogenous Leukemia


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute myeloid leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Male or female age 18 years old;
  2. Signed informed consent form
  3. AML either de novo or secondary [any subtype except acute promyelocytic leukemia (APL)] who either:
  4. are in relapse to standard therapy following an initial response
  5. failed primary induction therapy with no CR (failed 2 induction attempts) and for whom no other approved therapy is available
  6. newly diagnosed untreated AML in patients 65 years of age with high risk cytogenetics, if they are not candidates for standard available induction chemotherapy
  7. Must have baseline BM sample taken by BMA/BMB within 21 days prior to first dose of MCLA-117 for CLEC12A detection;
  8. Estimated life expectancy of at least 8 weeks;
  9. Eastern Cooperative Oncology Group (ECOG) performance status 2;
  10. Significant toxicities incurred as a result of previous anti-cancer therapy resolved to Grade 1 (NCI-CTCAE version 4.03);
  11. Acceptable laboratory values at screening;
  12. Male patients must agree to use an adequate and medically accepted method of contraception throughout the study and for at least 6 months after if their sexual partners are women of child bearing potential (WOCBP).
  13. WOCBP must be using highly effective and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 6 months after the study ;
  14. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug.
  15. Peripheral blast count </= 30,000/mm3 at the time of initiation of infusion on Cycle 1 Day 1.

Exclusion Criteria:

  1. Diagnosis of chronic myelogenous leukemia in blast crisis;
  2. Prior hematopoietic stem cell transplantation;
  3. Cancer chemotherapy within four weeks prior to start of MCLA-117;
  4. Previous treatment with radiotherapy, or immunotherapeutic agents, or receipt of live vaccines in the 4 weeks prior to study drug administration;
  5. Previous treatment with any other investigational agents within 4 weeks prior to MCLA-117 administration;
  6. Concurrent need of use of corticosteroids > 10 mg/day of oral prednisone or the equivalent, except topical preparations (e.g., topical creams, steroid inhaler, nasal spray or ophthalmic solution);
  7. Use of immunosuppressant medications within 4 weeks of MCLA-117 administration;
  8. Clinically active central nervous system (CNS) leukemia;
  9. Patients who are pregnant or lactating;
  10. Patients with an active infection or with an unexplained fever during screening or on the first scheduled day of dosing;
  11. Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
  12. Patients with known HIV, hepatitis B or C;
  13. Patients with New York Heart Association Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50%, or significant uncontrolled cardiac disease, current diagnosis of unstable angina, uncontrolled congestive heart failure, new myocardial infarction, or ventricular arrhythmia requiring medication;
  14. Prior malignancy (other than basal cell carcinoma and cervical in situ carcinoma) unless treated with a curative intend and without evidence of malignant disease for 1 year before screening. Patients with prior hematologic malignancies that have progressed to AML (such as Myelodysplastic syndrome, myeloproliferative neoplasms, bi-phenotypic leukemias, AcuteLymphocyticLeukemia) or AML that has relapsed are eligible;
  15. Urinary protein >2+ possibly indicative of renal disease. If the 24 hours urine protein shows a result of < 100 mg protein, subject can be eligible;
  16. Patients with any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results;
  17. WOCBP or males with a WOCB partners not willing to use highly effective and medically accepted methods of contraception for 6 months after last study drug administration.
  18. Need for concurrent other cytoreductive chemotherapy.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.